NIH works with Pfizer, AstraZeneca and Eli Lilly

NIH collaborate with Pfizer, AstraZeneca and Eli LillyFierce Biotech reported that The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly. The drug companies will offer up their data and investigators will have a chance to explore new uses, with a set of deal templates in place to help speed the process on 20 programs.

The investigators will have access to failed drugs to see if they can be repurposed for new uses.

Rod MacKenzie, group senior vice president, head of Pfizer PharmaTherapeutics Research and Development said “Pfizer has a rich history of partnering with the academic and public sectors to discover and develop innovative medicines…We believe that participating in this unique program, and making well researched molecules available to NIH’s broad network of researchers, is another important step in advancing a vibrant biomedical ecosystem.”

Are you looking for a new job in the pharmaceutical industry? Click here to see our latest pharmaceutical jobs in the UK

Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates

Posted in: Industry News, News
CK Logo in place of featured image